In a recent study posted to the bioRxiv preprint server, researchers at the University of Tuebingen and Imperial College London assessed humoral and cellular immune responses elicited by the recombinant adenoviral vector (rAdVV)- and messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines.
Researchers reported on the benefit of immunity developed by previous SARS-CoV-2 infection for overcoming the age-associated decline in COVID-19 vaccine effectiveness.